Helicobacter pylori and gastric malignancies

Helicobacter

Volumn 8, Issue SUPPL. 1, 2003, Pages 44-52

  Nardone, Gerardo ^a   Morgner, Andrea ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Epidemiology; Gastric cancer; Gastric lymphoma; Helicobacter pylori; Pathogenesis; Therapy

Indexed keywords

MOLECULAR MARKER;

CANCER INCIDENCE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DIETARY INTAKE; DNA MICROARRAY; GENE THERAPY; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; RISK FACTORS; STOMACH NEOPLASMS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0142026042     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2003.00160.x     Document Type: Review

References (65)

1. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-98. Aliment Pharmacol Ther 2003;17:665-76.
2. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and Survival in England and Wales 1971-98/1999. Aliment Pharmacol Ther 2003;17:655-64.
3. Ngoan LT, Mizoue T, Fujino Y, Tokui N, Yoshimura T. Dietary factors and stomach cancer mortality. Br J Cancer 2002;87:37.
4. Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC study Cohort I. Int J Cancer 2002;102:39-44.
5. Serafini M, Bellocco R, Wolk A, Ekstrom AM. Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 2002;123:985-91.
6. Weisburger JH, Chung FL, Weisburger JH, Chung FL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol 2002;40:1145-54.
7. Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II. Int J Cancer 2002;101:380.
8. Sasazuki S, Sasaki S, Tsugane S. Cigarette smoking, alcohol consumption and subsequent gastric cancer risk by subsite and histologic type. Int J Cancer 2002;101:560-6.
9. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249-60.
10. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680-7.
11. Thye T, Burchard GD, Nilius M, Muller-Myhsok B, Horstmann RD. Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. Am J Hum Genet 2003;72:448-53.
12. Niv Y. Family history of gastric cancer: should we test and treat for Helicobacter pylori? J Clin Gastroenterol, 2003;36:204-8.
13. Chang YW, Han YS, Lee DK, et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer, 2002;101:469-74.
14. Hsu PI, Hwang IR, Cittelly D, et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol, 2002;97:2231-8.
15. Koehler CI, Mues MB, Dienes HP, Kriegsmann J, Schirmacher P, Odenthal M. Helicobacter pylori genotyping in gastric adenocarcinoma and MALT lymphoma by multiplex PCR analyses of paraffin wax embedded tissues. Mol Pathol, 2003;56:36-42.
16. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer, 2003;103:815-21.
17. Li L, Genta RM, Go MF, Gutierrez O, Kim JG, Graham DY. Helicobacter pylori strain and the pattern of gastritis among first-degree relatives of patients with gastric carcinoma. Helicobacter 2002;7:349-55.
18. Meining A, Stolte M. Close correlation of intestinal metaplasia and corpus gastritis in patients infected with Helicobacter pylori. Z Gastroenterol 2002;40:557-60.
19. Bedoya A, Garay J, Sanzon F, et al. Histopathology of gastritis in Helicobacter pylori-infected children from populations at high and low gastric cancer risk. Hum Pathol, 2003;34:206-13.
20. Sepulveda A, Peterson LE, Shelton J, Gutierrez O, Graham DY. Histological patterns of gastritis in H. pylori-infected individuals with a family history of gastric cancer. Am J Gastroenterol 2002;97:1365-70.
21. Leung WK, Sung JJY. Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002;16:1209-16.
22. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut 2003;52:1-4.
23. Staibano S, Rocco A, Mezza E, De Rosa G, Budillon G, Nardone G. Diagnosis of chronic atrophic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. J Pathol 2002;198:47-54.
24. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16:1249-59.
25. Chetty R, Naidoo R, Tarin M, Sitti C. Chromosome 2p, 3p, 5q and 18q status in sporadic gastric cancer. Pathology 2002;34:275-81.
26. Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002;123:542-53.
27. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002;12:128-40.
28. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 2003;21:258-70.
29. Unger Z, Molnar B, Pronai L, Szaleczky E, Zagoni T, Tulassay Z. Mutant p53 expression and apoptotic activity of Helicobacter pylori positive and negative gastritis in correlation with the presence of intestinal metaplasia. Eur J Gastroenterol Hepatol 2003;15:389-93.
30. Niimi C, Goto H, Ohmiya N, et al. Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma. Am J Clin Pathol 2002;118:683-92.
31. Lan J, Xiong YY, Lin YX, et al. Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation. World J Gastroenterol 2003;9:54-8.
32. Berloco P, Russo F, Cariola F, et al. Low presence of p53 abnormalities in H pylori-infected gastric mucosa and in gastric adenocarcinoma. J Gastroenterol 2003;38:28-36.
33. Ebert MP, Yu J, Hoffmann J, Rocco A, et al. Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 2003;21:1708-14.
34. Chan AO, Wong BC, Lan HY, et al. Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. J Gastroenterol Hepatol, 2003;18:534-9.
35. Chan AO, Lam SK, Wong BC, et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003;52:502-6.
36. Hofler H, Becker KF. Molecular mechanisms of carcinogenesis in gastric cancer. Recent Results Cancer Res 2003;162:65-72.
37. Guo XL, Du Wang LESY, Fan CL, Li L, Wang P, Yuan Y. Association of cyclooxygenase-2 expression with H. pylori-cagA infection in gastric cancer. World J Gastroenterol 2003;9:246-9.
38. Wambura C, Aoyama N, Shirasaka D, et al. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 2002;7:129-38.
39. Meireles SI, Carvalho AF, Hirata R, et al. Differentially expressed genes in gastric tumors identified by cDNA array. Cancer Lett 2003;190:199-211.
40. Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012-7.
41. Kimura Y, Kikkawa N, Iijima S, et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 2003;6:34-9.
42. Takahashi I, Kakeji Y, Emi Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer. Current state and future prospects. Gastric Cancer 2003;6:28-33.
43. Tatematsu M, Nozaki K, Tsukamoto T. Helicobacter pylori infection and gastric carcinogenesis in animal models. Gastric Cancer 2003;6:1-7.
44. Han SU, Kim YB, Joo HJ, et al. Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. J Gastroenterol Hepatol 2002;17:253-61.
45. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003;63:942-50.
46. Ullrich A, Fischbach W, Blettner M. Incidence of gastric B-cell lymphomas: a population-based study in Germany. Ann Oncol 2002;13:1120-7.
47. Ben-Khelifa H, Sabbagh LC. Gastric lymphoma: Is the worldwide incidence rising? Gastrointest Endosc 2002;56:955-6.
48. Lehours P, Ruskone-Fourmestraux A, Lavergne A, Cantet F, Mégraud F, Groupe d'Etude des Lymphomes Digestifs (GELD) for the Federation Francaise de Cancerologie Digestive (FFCD). Which test to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003;98:291-5.
49. Seydel J, Ullrich A, Bender R, Fischbach W, Blettner M. Helicobacter pylori and carcinogenesis of gastric B-cell lymphomas. Int J Cancer 2003;104:646-9.
50. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003;Apr 3 [Epub ahead of print].
51. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon AC, de Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut 2003;52:912-3.
52. Fusaroli P, Buscarini E, Peyre S, et al. Interobserver agreement in staging gastric MALT lymphoma by EUS. Gastrointest Endosc 2002;55:662-8.
53. Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001;104:33-42.
54. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-94.
55. Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A, Dyer MJ, Chuang SS, Dogan A, Isaacson PG, Du MQ. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003;101:2547-50.
56. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002;99:3-9.
57. Remstein ED, Kurtin PJ, James CD, Wang XY, Meyer RG, Dewald GW. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002;161:63-71.
58. Chuang SS, Lee C, Hamoudi RA, Liu H, Lee PS, Ye H, Diss TC, Dogan A, Isaacson PG, Du MQ. High frequency of t(11;18) in gastric mucosa-associated lymphoid tissue lymphomas in Taiwan, including one patient with high-grade transformation. Br J Haematol 2003;120:97-100.
59. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003;101:2335-9.
60. Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas. Early analysis of the LY003 cooperative trial. Blood 2002;99:2541-4.
61. Thiede C, Wundisch T, Alpen B, et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001;19:1600-9.
62. Fischbach W, Goebler-Kolve M, Starostik P, Greiner A, Müller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002;360:547-8.
63. Thieblemont C, Dumontet C, Bouafia F, et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 2003;44:257-62.
64. Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-7.
65. Raderer M, Chott A, Drach J, et al. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002;13:1094-8.